1Globe Biomedical Co Ltd

BEIJING--( BUSINESS WIRE )--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2024. First Half of 2024 Financial Summary Sales for the six months ended June 30, 2024 were $121.3 million, compared to $140.4 million in the prior year period. The Company posted $10.9 million of net loss attributable to common shareholders, or a loss of $0.11 per basic and diluted share, in the six-month period ended June 30, 2024, compared to net income attributable to common shareholders of $14.0 million, or $0.14 per basic and $0.15 per diluted share, in the prior year period. Mr. Weidong Yin, Chairman, President and CEO of SINOVAC, commented, “In the first half of the year, SINOVAC focused on executing its regular vaccine business strategies. Although the COVID-19 pandemic is over, there are still challenges from various infectious diseases. SINOVAC provided vaccines in time during the epidemic of hepatitis A and influenza in Brazil, Chile and other countries to minimize the shortage of vaccine supplies, continuing our vital role similar to it in the COVID-19 pandemic period. Furthermore, it is great to see other progress in the international market where SINOVAC’s local joint venture won long-term public tenders in Türkiye.” Business Updates Hepatitis A Vaccine – Healive ® , the first and only WHO prequalified inactivated hepatitis A vaccine from China, is currently supplied both domestically and internationally. Healive ® ’s performance in international market substantially grew in the first half of 2024. Influenza Vaccine – SINOVAC has two influenza vaccine production plants. The plants, which comply with Chinese Good Manufacturing Practice (or “GMP”) guidelines and utilize environmental-friendly production process, enable automated production at commercial scale so that SINOVAC has more capacity to meet the growing global demand for high-quality influenza vaccines. SINOVAC’s influenza vaccines kept expanding its international market presence in 2024 by obtaining more overseas market approvals, won public tenders in Pakistan and were supplied to Chile for the flu emergency. A study conducted last year in the Philippines and Chile demonstrated that the immunogenicity induced by SINOVAC’s quadrivalent influenza vaccine was non-inferior and the geometric mean titers (or “GMT”) were even higher in individuals aged 3 years and older, when compared with the control vaccine which was widely used. The research result was published in Vaccines in 2024. Furthermore, SINOVAC completed phase III clinical trials of quadrivalent influenza in infants and toddlers aged 6-35 months in the first half of 2024. Varicella Vaccine – SINOVAC’s live attenuated varicella vaccine, the first WHO prequalified (or “PQ”) Chinese varicella vaccine, was successfully supplied to more countries this year. SINOVAC's varicella vaccine, which had been previously approved for children aged 12 months to 12 years old, was approved by China NMPA for use in adolescents and adults aged 13 years old and above in June 2024. SINOVAC’s varicella vaccine obtained its first international GMP certificate in the Philippines in January 2024. Hand Foot and Mouth Disease Vaccine – SINOVAC’s Enterovirus 71 (or “EV71”) Vaccine, Inlive ® , has already safeguarded millions of children in China. In 2023, SINOVAC initiated phase I and II clinical trials of its bivalent enterovirus inactivated vaccine, which aims to protect against hand, foot and mouth disease (or “HFMD”) caused by EV71 and coxsackievirus 16 (or “CA16”). CA16 is the dominant strain and is widespread in China and other Asian regions. At present, the enrollment of all the participants of this study has been completed. Enterovirus Type 71 Vaccine (Vero cell), Inactivated - Inlive ® ’ project participated by SINOVAC won second prize of the PRC National Science and Technology Progress Award 2023. In 2024, SINOVAC's EV71 vaccine was approved for use in Macao, China. Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains – SINOVAC's Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (0.5ml/vial) (or "sIPV") received WHO PQ on June 2, 2022. Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (Five-Dose) (2.5ml/vial) (or "msIPV") was authorized in April 2024 by the China NMPA for market use. Since msIPV is mainly for UNICEF and PAHO procurement, SINOVAC is currently applying msIPV for WHO PQ approval so supply msIPV to the above international organizations can be achieved at the earliest date. Reassortant Rotavirus Vaccine – SINOVAC has initiated phase I clinical trials of its Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell). The vaccine covers six rotavirus serotypes, G1, G2, G3, G4, G9, and P1A. It is one of the rotavirus vaccines with a broad-spectrum protection currently marketed or under development in the world. By the first half of 2024, this phase I clinical trial has finished enrollment and vaccination of adults and children participants, and enrollment of infants participants is ongoing and expected to be finished in the third quarter of 2024. Adsorbed Tetanus Vaccine – The results of phase I/III clinical study of the adsorbed tetanus vaccine developed by SINOVAC were favorable. The antibody conversion rate of volunteers in the phase III clinical trial reached 99.48% in 30 days after vaccination, which reached the non-inferiority standard; the geometric mean concentration (or “GMC”) of antibodies reached statistical superiority. Commercial Developments – SINOVAC made significant progress in commercial development in the first half of 2024. In Türkiye, the first overseas joint venture company invested by SINOVAC won two long-term public tenders for the hepatitis A vaccine and varicella vaccine. SINOVAC's extensive expertise and experience in vaccine R&D and production, as well as its successful track record in establishing vaccine facilities, will play a pivotal role in the joint venture. Unaudited Financial Results for the First Half of 2024 Sales for the first half of 2024 were $121.3 million compared to $140.4 million in the prior year period. Although Healive ® ’s sales for the first half of 2024 increased due to international market growth, however, as newborn rates in China continue to decline, sales of EV71 vaccines, which are primarily used in young children, have been impacted, resulting in a decrease in the Company’s revenue in the first half of 2024. Selling, general and administrative expenses in the first half of 2024 were $206.3 million, compared to $231.0 million in the prior year period. The decrease was mainly due to lower employee incentive expenses associated with a COVID-19 employee incentive plan established in 2022. R&D expenses in the first half of 2024 were $144.1 million, compared to $151.1 million in the prior year period. Net loss in the first half of 2024 was $68.6 million, compared to a net loss of $30.0 million in the prior year period. Net loss attributable to common shareholders was $10.9 million, or a loss of $0.11 per basic and diluted share, in the first half of 2024, compared to a net income attributable to common shareholders of $14.0 million, or $0.14 per basic and $0.15 per diluted share, in the prior year period. As the Company announced on February 22, 2019, the Company’s board of directors determined that certain shareholders became acquiring persons, as defined in the Company’s rights agreement (“Rights Agreement”), under which a trigger event occurred. As a result, the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued common and preferred shares, basic and diluted loss per share for the first half of 2024 would be $0.11. Non-GAAP adjusted EBITDA was $204.2 million loss in the first half of 2024, compared to $346.6 million loss in the prior year period. Non-GAAP net loss was $82.3 million in the first half of 2024, compared to $120.9 million net loss in the prior year period. Non-GAAP diluted loss per share in the first half of 2024 was $0.16 compared to a loss of $0.32 per share in the prior year period. Non-GAAP diluted loss per share in the first half of 2024, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $0.22. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this news release. As of June 30, 2024, cash and cash equivalents and restricted cash totaled $1.1 billion, compared to $1.3 billion as of December 31, 2023. In the first half of 2024, net cash used in operating activities was $438.9 million, net cash provided by investing activities was $436.8 million reflecting the net position of short-term investment redemptions over purchases, and net cash used in financing activities was $171.2 million. The Company’s first half of 2024 financial statements are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company’s independent registered accounting firm. Legal Proceedings As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the “Antigua Judgment”), finding the Company fully in favor, dismissing 1Globe’s claim and declaring the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s rights or shareholding or otherwise distributing the exchange shares (the “Exchange Shares”) to the Company’s shareholders who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean Supreme Court, Court of Appeal (the “Court of Appeal”) on December 9, 2021, upholding the Antigua Judgment in each point. 1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the “Privy Council”), and the hearing of the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement. The final substantive hearing before the Privy Council took place on July 10 to 11, 2024. The Privy Council refused 1Globe permission to appeal on certain arguments in relation to the validity of the Rights Agreement, and reserved its judgment for other arguments on that ground of appeal, and in relation to whether to grant 1Globe relief in relation to the outcome of the AGM vote. The judgment will be delivered in writing at a later date. The appeal outcome is therefore pending. As previously disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims and a third-party complaint against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stayed the Delaware litigation pending the final outcome of 1Globe’s appeal of the Antigua Judgment. Separately, Heng Ren Investments LP (“Heng Ren”) filed suits against SINOVAC and Weidong Yin on May 31, 2019 in Massachusetts state court for the alleged breach of fiduciary duties and wrongful equity dilution. SINOVAC moved the matter from the state court to the United States District Court for the District of Massachusetts. Heng Ren alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that SINOVAC aided and abetted breaches of fiduciary duties and that both SINOVAC and Mr. Yin engaged in wrongful equity dilution. Heng Ren requested damages, attorney fees, and prejudgment interest. In July 2021, SINOVAC moved to dismiss Heng Ren’s amended complaint in the federal court in Massachusetts. On March 4, 2022, the court granted the motion as to the breach of fiduciary duty claims and denied the motion as to the wrongful equity dilution claim and denied reconsideration of its decision on the motion. On June 13, 2024, the parties stipulated to a discontinuance of the action with prejudice. SINOVAC did not incur any material expense in connection with the action. On September 6, 2023, MW Gestion, an institutional asset manager based in France, filed a class action complaint on behalf of all SINOVAC shareholders against SINOVAC; Weidong Yin; and other managers and directors of SINOVAC, including Nan Wang, Simon Anderson, Yuk Lam Lo, Kenneth Lee, Meng Mei, and Shan Fu (the “Individual Defendants” and collectively with SINOVAC the “SINOVAC Defendants”); and Wilmington Trust National Association. MW Gestion alleges breach of contract, breach of fiduciary duty, and wrongful dilution claims against the SINOVAC Defendants, as well as aiding and abetting breach of contract and breach of fiduciary duty against the Individual Defendants. MW Gestion’s claims stem from a private investment in public equity transaction on July 2, 2018, and SINOVAC’s implementation of its Rights Agreement on February 22, 2019. SINOVAC and certain other defendants filed a motion to dismiss all claims on November 20, 2023, and the motion was fully briefed as of February 27, 2024. A hearing on the motion to dismiss has been scheduled for September 4, 2024. Status of Exchange Shares and Trading in the Company’s Shares As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgment and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regard to trading of the Company’s common shares. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc. The COVID-19 vaccine, CoronaVac ® , has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive ® , passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive ® , is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine, Panflu.1 ® , which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu ® , to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company’s website at www.sinovac.com . Safe Harbor Statement This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, SINOVAC uses the following non-GAAP financial measures: non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share. For more information on these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures” in this results announcement. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that SINOVAC includes in net income and diluted earnings (loss) per share. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share should not be considered in isolation or construed as an alternative to income from operations, net income (loss), diluted earnings (loss) per share, or any other measure of performance or as an indicator of SINOVAC’s operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. Non-GAAP adjusted EBITDA represents net income (loss) and excludes interest and financing expenses, interest income, net other income (expenses) and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based compensation expenses, amortization and depreciation that SINOVAC does not believe are reflective of the core operating performance during the periods presented. Non-GAAP net income (loss) represents net income (loss) before share-based compensation expenses and foreign exchange gain or loss. Non-GAAP diluted earnings (loss) per share represents non-GAAP net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options. SINOVAC BIOTECH LTD. Consolidated Balance Sheets As of June 30, 2024 and December 31, 2023 (Expressed in thousands of U.S. Dollars) June 30, 2024 December 31, 2023 Current assets Cash and cash equivalents $ 1,072,350 $ 1,270,131 Restricted cash 2,779 5,166 Short-term investments 9,502,185 9,953,042 Accounts receivable - net 370,168 440,019 Inventories 153,524 139,874 Prepaid expenses and deposits 12,724 11,621 Amounts due from related parties 23,847 - Income tax receivable 10,703 10,703 Total current assets 11,148,280 11,830,556 Property, plant and equipment – net 934,614 979,617 Prepaid land lease payments 62,916 65,540 Intangible assets - net 7,844 8,520 Long-term prepaid expenses 24 24 Long-term investments 681,345 684,285 Prepayments for acquisition of equipment 4,338 6,772 Deferred tax assets 32,798 29,790 Right-of-use assets 15,346 45,525 Other non-current assets 9,432 7,345 Total assets 12,896,937 13,657,974 Current liabilities Short-term bank loans and current portion of long-term bank loans 179,349 76,089 Accounts payable and accrued liabilities 641,579 973,949 Income tax payable 28,720 41,258 Deferred revenue 6,173 20,127 Deferred government grants 805 1,586 Dividend payable 119,374 29,089 Lease liability 2,451 5,806 Total current liabilities 978,451 1,147,904 Deferred government grants 5,984 5,865 Long-term bank loans 130,320 177,817 Deferred tax liability 262,174 263,711 Lease liability 12,388 39,271 Other non-current liabilities 429 439 Deferred revenue 195 200 Total long-term liabilities 411,490 487,303 Total liabilities 1,389,941 1,635,207 Commitments and contingencies Equity Preferred stock 15 15 Common stock 100 100 Additional paid-in capital 541,258 541,258 Accumulated other comprehensive loss (539,415) (490,055) Statutory surplus reserves 1,539,584 1,539,584 Accumulated earnings 7,107,644 7,118,516 Total shareholders' equity 8,649,186 8,709,418 Non-controlling interests 2,857,810 3,313,349 Total equity 11,506,996 12,022,767 Total liabilities and equity $ 12,896,937 $ 13,657,974 SINOVAC BIOTECH LTD. Consolidated Statements of Comprehensive Income (Loss) For the six months ended June 30, 2024 and 2023 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended June 30 2024 2023 Sales $ 121,339 $ 140,404 Cost of sales 40,836 188,409 Gross profit (loss) 80,503 (48,005) Selling, general and administrative expenses 206,347 231,048 Provision for (recovery of) doubtful accounts (663) 386 Research and development expenses 144,052 151,132 Loss on disposal of property, plant and equipment 5,387 312 Government grants recognized in income (1,044) (92) Total operating expenses 354,079 382,786 Operating income (loss) (273,576) (430,791) Interest and financing expenses (2,175) (264) Interest income 44,060 29,589 Other income, net 166,481 337,856 Loss before income taxes (65,210) (63,610) Income tax benefit (expense) (3,432) 33,597 Net loss (68,642) (30,013) Less: loss attributable to non-controlling interests 60,745 46,931 Net income (loss) attributable to shareholders of Sinovac (7,897) 16,918 Preferred stock dividends (2,975) (2,958) Net income (loss) attributable to common shareholders of Sinovac (10,872) 13,960 Net loss (68,642) (30,013) Other comprehensive income, net of tax of nil Foreign currency translation adjustments (194,758) (448,477) Unrealized gain 69,612 6,917 Comprehensive loss (193,788) (471,573) Less: comprehensive loss attributable to non-controlling interests 136,531 217,305 Comprehensive loss attributable to shareholders of Sinovac (57,257) (254,268) Earnings per share Basic net income per share (0.11) 0.14 Diluted net income per share (0.11) 0.15 Weighted average number of shares of common stock outstanding Basic 99,638,043 99,576,600 Diluted 99,638,043 114,227,276 SINOVAC BIOTECH LTD. Consolidated Statements of Cash Flows For the six months ended June 30, 2024 and 2023 (Expressed in thousands of U.S. Dollars) Six months ended June 30 2024 2023 Operating activities Net loss $ (68,642) $ (30,013) Adjustments to reconcile net income to net cash provided by operating activities: Deferred income taxes (3,718) (32,124) Inventory provision 8,340 12,624 Provision for (recovery of) doubtful accounts (663) 386 Loss on disposal of property, plant and equipment 5,387 312 Depreciation of property, plant and equipment 67,747 82,484 Amortization of prepaid land lease payments 1,093 1,138 Amortization of intangible assets 501 527 Government grants recognized in income (1,044) (92) Loss from equity method investments 7,640 374 Investment income (135,971) (75,612) Changes in: Accounts receivable 62,928 90,434 Amounts due from related parties (23,847) - Inventories (25,311) (23,296) Other non-current assets (2,273) 2,785 Income tax payable (11,676) (5,824) Prepaid expenses and deposits (3,272) 1,583 Deferred revenue (13,595) (2,074) Accounts payables and accrued liabilities (302,521) (47,208) Deferred governments - (16,813) Other non-current liabilities - 418 Net cash used in operating activities (438,897) (39,991) Financing activities Proceeds from bank loans 136,207 209,587 Repayments of bank loans (74,153) (150) Proceeds from issuance of common stock, net of share issuance costs - 676 Dividend paid to non-controlling shareholders (233,375) (1,616) Proceeds from subsidiary's financing Government grants received 141 8,668 Repayments of loan from a non-controlling shareholder - (1) Net cash provided by (used in) financing activities (171,180) 217,164 Investing activities Purchase of short-term investments (3,427,917) (6,628,110) Proceeds from redemption of short-term investments 3,925,995 4,013,372 Proceeds from disposal of equipment 107 37 Prepaid land lease payments - - Acquisition of property, plant and equipment (57,115) (92,942) Acquisition of intangible assets (18) - Purchase of long-term investments (4,224) (24,792) Distributions of equity method investees - 1,342 Proceeds from sale or maturity of long-term investments - 146 Net cash provided by (used in) investing activities 436,828 (2,730,947) Effect of exchange rate changes on cash and cash equivalents and restricted cash (26,919) (85,843) Decrease in cash and cash equivalents and restricted cash (200,168) (2,639,617) Cash and cash equivalents and restricted cash, beginning of period 1,275,297 4,286,377 Cash and cash equivalents and restricted cash, end of period 1,075,129 1,646,760 SINOVAC BIOTECH LTD. Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures For the six months ended June 30, 2024 and 2023 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended June 30 2024 2023 (Unaudited) (Unaudited) Net loss $ (68,642) $ (30,013) Adjustments: Depreciation and amortization 69,341 84,149 Interest income, net of interest and financing expenses (41,885) (29,325) Other income, net (166,481) (337,856) Income tax expense (benefit) 3,432 (33,597) Non-GAAP adjusted EBITDA (204,235) (346,642) Net loss (68,642) (30,013) Add: Foreign exchange gain (13,695) (90,851) Non-GAAP net loss (82,337) (120,864) Net income (loss) attributable to common shareholders of Sinovac (10,872) 13,960 Add: Preferred stock dividends 2,975 2,958 Net income (loss) attributable to common shareholders of Sinovac for computing diluted earnings per share (7,897) 16,918 Add: Non-GAAP adjustments to net income (8,191) (53,349) Non-GAAP net income (loss) attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share (16,088) (36,431) Weighted average number of shares on a diluted basis 99,638,043 114,227,276 Diluted earnings (loss) per share (0.08) 0.15 Add: Non-GAAP adjustments to net income per share (0.08) (0.47) Non-GAAP diluted loss per share (0.16) (0.32)

来源：企业公告    整理：wangxinglai2004 近日，因信息披露违规，山东未名医药及相关责任人收到了中国证监会开除的《行政处罚决定书》，其中潘爱华被给与10年证券市场禁入处罚，罗德顺、杨晓敏分别被给与5年证券市场禁入处罚，山东未名医药及10名参与者被处罚合计935万。 经查明，未名医药存在以下违法事实：    01 未按规定披露关联方及非经营性关联交易   2018年2月至2019年7月，北京北大未名生物工程集团有限公司为未名医药控股股东，王某平为未名医药持股5%以上的股东；未名集团持有北京未名博思生物智能科技开发有限公司 68.75%的股份，持有长春未名生物经济科技发展有限公司85%的股份。 根据规定，未名集团、未名博思、长春未名系未名医药关联法人，王某平系未名医药关联自然人。   2018年2月，未名医药全资子公司未名生物医药有限公司以预付采购款的名义通过厦门市安科瑞仪器有限公司等公司银行账户向王某平银行账户转入1,800万元。   2018年3月至2019年6月，厦门未名及其控股子公司天津未名生物医药有限公司以退还采购预付款、支付合同预付款、借支市场推广备用金等名义，直接或者通过深圳市安科瑞仪器有限公司、上海百迈博制药有限公司等公司和厦门未名部分员工的银行账户间接向未名博思银行账户转入47,220万元。   2018年9月至2019年7月，厦门未名及天津未名通过银行承兑汇票背书、厦门市栢泰生物科技有限公司等公司过账的方式，代未名集团偿还债务42,000万元。   2018年12月至2019年3月，厦门未名以支付工程预付款、研究开发经费和报酬的名义通过福建百胜祥建筑工程有限公司、上海张江生物技术有限公司等公司银行账户向长春未名银行账户转入4,388.32万元。   上述非经营性关联交易累计发生额95,408.32万元。未名医药应当及时披露上述关联交易，但未按规定披露。   2018年上半年、2018年全年、2019年上半年未名医药未披露与上述关联方的关联交易总额分别为37,800万元、60,848.32万元和34,060万元，分别占最近一期经审计净资产的13.23%、22.03%和12.33%，占当期净资产的13.2%、22.03%和12.22%。 未名医药应当在2018年半年度报告、2018年年度报告、2019年半年度报告中披露关联方未名博思、长春未名以及上述关联交易事项，但未予披露，导致相关定期报告存在重大遗漏。   根据当事人违法行为的事实、性质、情节与社会危害程度，依据2005年《证券法》第一百九十三条第一款、第三款的规定，对未名医药未按规定及时披露关联交易，披露的2018年半年度报告、2018年年度报告、2019年半年度报告存在重大遗漏的违法行为，我局决定：   对山东未名生物医药股份有限公司责令改正，给予警告，并处以60万元罚款。   对潘爱华给予警告，并处以90万元罚款，其中作为直接负责的主管人员罚款30万元，作为实际控制人罚款60万元。   对杨晓敏、罗德顺、赵芙蓉、丁学国给予警告，并分别处以20万元罚款。   对赖闻博给予警告，并处以10万元罚款。   对方言给予警告，并处以5万元罚款。    02 未按规定及时披露重要合同及合同履行的重大进展   未名医药在未履行董事会、股东大会审议程序的情况下，与厦门未名、杭州强新生物科技有限公司签署《关于未名生物医药有限公司之增资协议》，约定杭州强新以288,485万元溢价认购厦门未名6,767.49万元新增注册资本，以获得厦门未名34%股权。该协议的成交金额占未名医药最近一期经审计净资产的120.8%。协议签订后，厦门未名于2022年5月18日完成股东信息工商登记变更，更多精彩内容回顾请看： 拉闸断电致北京科兴疫苗损失 未名医药子公司被判赔近1600万 核心子公司股权“被偷卖”，未名三收函 增资协议属于未名医药订立的重要合同，厦门未名变更工商登记属于合同履行的重大进展，未名医药应当及时予以披露，但未按规定披露。  根据当事人违法行为的事实、性质、情节与社会危害程度，依据《证券法》第一百九十七条第一款的规定，对未名医药未按规定及时披露重要合同及合同履行重大进展的违法行为，我局决定：   对山东未名生物医药股份有限公司责令改正，给予警告，并处以250万元罚款。   对潘爱华给予警告，并处以150万元罚款。  对罗德顺给予警告，并处以120万元罚款。对杨晓敏给予警告，并处以100万元罚款。对赵辉给予警告，并处以30万元罚款。对徐若然、张一诺给予警告，并分别处以20万元罚款。   编语：针对违规事件二，未名医药曾在回复问询函中表示失去了厦门未名控制权，主要内容如下： 杭州强新取得厦门未名34%股权的具体方式、交易金额、定价依据及其他重要协议条款经查阅公司内部董事会文件，未查询到董事会有关该事项的召集通知，也未查询到董事会有关该事项的会议记录。同样未查询到股东大会召集通知和股东大会会议记录，公司也未就此事发出公告信息。 该交易事项根据工商变更记录发生于2022年5月18日，经核对内部用印流程和用印记录，公司内部并没有此事项的用印申请流程和记录，公章这个时期在上海办公室保管，上海因疫情封城多日，物理上无法盖章送出文件。 本次杭州强新取得厦门未名34%股权涉及的其他重要协议条款如下： （1）《决定书》第三条规定，“《厦门未名章程》第二十一条所列事项，须经代表三分之二以上表决权的股东通过。”这意味着厦门未名的重要事项必须经过34%的股东杭州强新同意。 （2）《厦门未名章程》除了出资额和注册资本变化，还增加了第二十四条，重申了前述《决定书》第三条规定。而《厦门未名章程》第二十一条有二十五款，基本覆盖了厦门未名的所有经营事项。这意味着厦门未名的几乎所有经营事项必须经过34%的股东杭州强新同意。 （3）《厦门未名章程》山东未名生物医药股份有限公司推荐2名董事，杭州强新生物科技有限公司推荐1名董事。当山东未名生物医药股份有限公司控股股东发生改变时，原控股股东面确认对山东未名生物医药股份有限公司失去控制地位，则董事由杭州强新生物科技有限公司推荐2名，山东未名生物医药股份有限公司推荐1名董事。”这意味着在目前未名医药控股股东已经发生变更的情形下，只需要原控股股东的一份书面通知，未名医药就失去了对厦门未名董事会的控制权。 《未名医药生物医药有限公司章程》签署日期为2022年5月15日，股东签章页具有本公司公章印记及本公司原法定代表人潘爱华签字字样。公司无法判断以上文件的真实性，以及其确定来源。本公司认为本公司全资子公司厦门未名出现核心资产流失和重大利益被侵占，该交易既不合规也不合法。 以上内容详见：非法交易&公司失控？知名药企8月连收4份关注函！ 03 最终处罚： 综合以上两项处罚意见，我局决定：   对山东未名生物医药股份有限公司责令改正，给予警告，并处以310万元罚款。   对潘爱华给予警告，并处以240万元罚款。   对罗德顺给予警告，并处以140万元罚款。   对杨晓敏给予警告，并处以120万元罚款。   对赵辉给予警告，并处以30万元罚款。   对赵芙蓉、丁学国、徐若然、张一诺给予警告，并分别处以20万元罚款。   对赖闻博给予警告，并处以10万元罚款。   对方言给予警告，并处以5万元罚款。   鉴于潘爱华违法情节较为严重，罗德顺、杨晓敏违法情节严重，依据2005年《证券法》第二百三十三条、《证券法》第二百二十一条和《证券市场禁入 规定》，我局决定： 对潘爱华采取10年证券市场禁入措施，对罗德顺、杨晓敏分别采取5年证券市场禁入措施，自我局宣布决定之日起，在禁入期间内，除不得继续在原机构从事证券业务或者担任原上市公司、非上市公众公司董事、监事、高级管理人员职务外，也不得在其他任何机构中从事证券业务或者担任其他上市公司、非上市公众公司董事、监事、高级管理人员职务。

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual report can be accessed on the Company's investor relations website at . The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023. Second Half and Full Year 2023 Financial Summary Sales for the six months ended December 31, 2023 were $307.9 million, compared to $280.5 million in the prior year period. Sales in 2023 were $448.3 million, compared to $1.5 billion in the prior year. The Company posted $119.9 million of net loss attributable to common shareholders, or a loss of $1.20 per basic and diluted share, in the six months ended December 31, 2023, compared to net loss attributable to common shareholders of $373.7 million, or a loss of $3.76 per basic and diluted share, in the prior year period. The Company posted $105.9 million of net loss attributable to common shareholders, or a loss of $1.06 per basic and diluted share in 2023, compared to net income attributable to common shareholders of $107.9 million, or $1.08 per basic and $1.00 per diluted share, in the prior year period. Mr. Weidong Yin, Chairman, President and CEO of SINOVAC, commented “In 2023, SINOVAC has gradually adjusted from the state of mass supply of COVID-19 vaccine against pandemic back to normal operational status. I am pleased to see that the top line of our regular products still maintained growth in the year of 2023. After experiencing three years of the COVID-19 pandemic, the world is still facing the threat of various infectious diseases in 2023. As a leading biopharmaceutical products provider in China, SINOVAC continues to invest additional resources in R&D and production of vaccines, and keeps exploring additional opportunities in a broader biopharmaceutical industry. It is great to see every progress of our pipeline products, such as the recent approval of 5-dose sIPV from National Medical Products Administration (NMPA) and the approval of clinical trial for reassortant hexavalent rotavirus vaccine. Meanwhile, we are maintaining a strong international presence by providing high quality vaccines and localized production outside of China.” Business Updates Hepatitis A Vaccine – Healive®, the first and only WHO prequalified inactivated hepatitis A vaccine from China, is currently supplied both domestically and internationally. Healive®’s performance in public tender market in China was further improved in 2023. Influenza Vaccine – A new and state-of-the-art influenza vaccine production line started operations in Beijing. The plant, which complies with Chinese Good Manufacturing Practice guidelines and utilizes green production processes, enables automated production at scale that expands SINOVAC’s capacity to meet the growing global demand for high-quality influenza vaccines. SINOVAC’s influenza vaccines expand international market accessibility in 2023 by obtaining more overseas market approvals, such as in Pakistan and Chile. A study conducted recently in the Philippines and Chile demonstrated that the immunogenicity induced by SINOVAC’s quadrivalent influenza vaccine was non-inferior and the geometric mean titers were even higher in individuals aged 3 years and older, when compared with the control vaccine which was widely used. Varicella Vaccine – SINOVAC’s live attenuated varicella vaccine, the first WHO prequalified Chinese varicella vaccine, was successfully supplied to Türkiye this year. The varicella vaccine was also registered in Lebanon and Kenya in 2023. Hand Foot and Mouth Disease Vaccine – SINOVAC’s Enterovirus 71 (EV71) vaccine, Inlive®, has already safeguarded millions of children in China. In 2023, SINOVAC has initiated phase I clinical trials of its bivalent enterovirus inactivated vaccine, which aims to protect against hand, foot and mouth disease (HFMD) caused by enterovirus 71 (EV71) and coxsackievirus 16 (CA16). Strategic Developments - We achieved several milestones in the strategic development in 2023. In Türkiye, our first joint venture with a local partner has successfully completed construction of a vaccine production plant, and a GMP certificate was obtained from the Turkish Medicines and Medical Devices Agency. In Latin America, we participated in a tender issued by the government of Bogota, Colombia, for localizing human vaccine production, and we were successfully selected as the exclusive strategic partner with BogotáBio, a local vehicle for the localization project, which aims to build the first local human vaccine production facility with municipal partner in Colombia’s capital of Bogota. SINOVAC's extensive expertise and experience in vaccine R&D and production, and its successful track record in establishing vaccine manufacturing facilities will play a pivotal role in the new venture. At the end of 2023, SINOVAC completed an investment in Synermore Biologics (Suzhou) Co., Ltd., a company which focuses on the development and production of monoclonal antibody drugs in the fields of infectious diseases, malignant tumors and autoimmune diseases. The investment marks a key step for SINOVAC entering into the novel antibody drugs field. Unaudited Financial Results for the Second Half of 2023 Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period. The increase was mainly due to increased sales of our influenza vaccines. Selling, general and administrative expenses in the second half of 2023 were $235.3 million, compared to $667.7 million in the prior year period. The decrease was mainly due to lower expenses incurred in the COVID-19 employee incentive plan which was established in 2022. R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period. Net loss in the second half of 2023 was $228.3 million, compared to net loss of $702.3 million in the prior year period. Net loss attributable to common shareholders was $119.9 million, or a loss of $1.20 per basic and diluted share, in the second half of 2023, compared to a net loss attributable to common shareholders of $373.7 million, or a loss of $3.76 per basic and diluted share, in the prior year period. As the Company announced on February 22, 2019, the Company’s board of directors determined that certain shareholders became acquiring persons, as defined in the Company’s rights agreement (“Rights Agreement”), under which a trigger event occurred. As a result, the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued common and preferred shares, basic and diluted loss per share for the second half of 2023 would be $1.63. Non-GAAP adjusted EBITDA was a loss of $111.6 million in the second half of 2023, compared to a loss of $998.7 million in the prior year period. Non-GAAP net loss was $183.0 million in the second half of 2023, compared to a net loss of $805.8 million in the prior year period. Non-GAAP diluted loss per share in the second half of 2023 was $0.93 compared to a loss of $4.38 per share in the prior year period. Non-GAAP diluted loss per share in the second half of 2023, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $1.29. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company’s independent registered accounting firm. Financial Results for the Twelve Months Ended December 31, 2023 Sales in 2023 were $448.3 million, a decrease from $1.5 billion in the prior year. The decrease was due to decreased sales of CoronaVac®. Selling, general and administrative expenses in 2023 were $466.3 million, compared to $823.5 million in the prior year. The decrease was mainly due to lower expenses incurred in the COVID-19 employee incentive plan which was established in 2022. R&D expenses in 2023 were $344.5 million, compared to $442.1 million in the prior year. The Company continued to invest in the advancement of pipeline vaccines in 2023. Net loss in 2023 was $258.4 million, compared to a net income of $88.1 million in the prior year. Net income decreased primarily due to decreased sales. Net loss attributable to common shareholders was $105.9 million, or a loss of $1.06 per basic and diluted share, compared to net income attributable to common shareholders of $107.9 million, or $1.08 per basic and $1.00 per diluted share, in the prior year. Excluding the implementation of the Rights Agreement, as described above, and the newly-issued common and preferred shares, basic and diluted loss per share for 2023 would be $1.39. Non-GAAP adjusted EBITDA was a loss of $458.3 million in 2023, compared to a loss of $309.5 million in the prior year. Non-GAAP net loss in 2023 was $303.9 million, compared to a net loss of $177.0 million in the prior year. Non-GAAP diluted loss per share in 2023 was $1.32, compared to a loss of $0.37 per share in the prior year. Non-GAAP diluted loss per share in 2023, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $1.84 per share. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. As of December 31, 2023, cash and cash equivalents and restricted cash totaled $1.3 billion, compared to $4.3 billion as of December 31, 2022. In 2023, net cash provided by operating activities was $104.0 million, net cash used in investing activities was $2.9 billion, and net cash used in financing activities was $76.1 million. As of December 31, 2023, the Company had $76.1 million in bank loans due within one year. The Company expects that its current cash position will be able to support its operations for at least the next 12 months. Legal Proceedings As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the “Antigua Judgment”), finding the Company fully in favor, dismissing 1Globe’s claim and declaring the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s rights or shareholding or otherwise distributing the exchange shares (the “Exchange Shares”) to the Company’s shareholders who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean Supreme Court, Court of Appeal (the “Court of Appeal”) on December 9, 2021, upholding the Antigua Judgment in each point. 1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the “Privy Council”), and the hearing of the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement. The final substantive hearing before the Privy Council is listed for July 10 to 11, 2024. The judgment will be reserved and delivered in writing at a later date. The appeal outcome is therefore pending. As previously disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims and a third-party complaint against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stated that the Delaware litigation was pending the final outcome of 1Globe’s appeal of the Antigua Judgment. Separately, Heng Ren Investments LP (“Heng Ren”) filed suits against SINOVAC and Weidong Yin on May 31, 2019 in Massachusetts state court for the alleged breach of fiduciary duties and wrongful equity dilution. SINOVAC moved the matter from the state court to the United States District Court for the District of Massachusetts. Heng Ren alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that SINOVAC aided and abetted breaches of fiduciary duties and that both SINOVAC and Mr. Yin engaged in wrongful equity dilution. Heng Ren requested damages, attorney fees, and prejudgment interest. In July 2021, SINOVAC moved to dismiss Heng Ren’s amended complaint in the federal court in Massachusetts. On March 4, 2022, the court granted the motion as to the breach of fiduciary duty claims and denied the motion as to the wrongful equity dilution claim and denied reconsideration of its decision on the motion. SINOVAC has answered the complaint. Pursuant to the current schedule, the close of fact discovery is April 26, 2024, the deadline for initial summary judgment motions is August 23, 2024, and, should the case not be resolved through settlement or at summary judgment, trial is set to begin on December 9, 2024. On September 6, 2023, MW Gestion, an institutional asset manager based in France, filed a class action complaint on behalf of all SINOVAC shareholders against SINOVAC; Weidong Yin; and other managers and directors of SINOVAC, including Nan Wang, Simon Anderson, Yuk Lam Lo, Kenneth Lee, Meng Mei, and Shan Fu (the “Individual Defendants” and collectively with SINOVAC the “SINOVAC Defendants”); and Wilmington Trust National Association. MW Gestion alleges breach of contract, breach of fiduciary duty, and wrongful dilution claims against the SINOVAC Defendants, as well as aiding and abetting breach of contract and breach of fiduciary duty against the Individual Defendants. MW Gestion’s claims stem from a private investment in public equity transaction on July 2, 2018, and SINOVAC’s implementation of its Rights Agreement on February 22, 2019. SINOVAC and certain other defendants filed a motion to dismiss all claims on November 20, 2023, and the motion was fully briefed as of February 27, 2024. Status of Exchange Shares and Trading in the Company’s Shares As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgment and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regard to trading of the Company’s common shares. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company’s website at . Safe Harbor Statement This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, SINOVAC uses the following non-GAAP financial measures: non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share. For more information on these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures” in this results announcement. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that SINOVAC includes in net income and diluted earnings (loss) per share. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share should not be considered in isolation or construed as an alternative to income from operations, net income (loss), diluted earnings (loss) per share, or any other measure of performance or as an indicator of SINOVAC’s operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. Non-GAAP adjusted EBITDA represents net income (loss) and excludes interest and financing expenses, interest income, net other income (expenses) and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based compensation expenses, amortization and depreciation that SINOVAC does not believe are reflective of the core operating performance during the periods presented. Non-GAAP net income (loss) represents net income (loss) before share-based compensation expenses and foreign exchange gain or loss. Non-GAAP diluted earnings (loss) per share represents non-GAAP net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options. SINOVAC BIOTECH LTD. Consolidated Balance Sheets As of December 31, 2023 and 2022 (Expressed in thousands of U.S. Dollars) December 31, 2023 December 31, 2022 Current assets Cash and cash equivalents $ 1,270,131 $ 4,278,124 Restricted cash 5,166 8,253 Short-term investments 9,953,042 7,034,569 Accounts receivable - net 440,019 537,118 Inventories 139,874 180,719 Prepaid expenses and deposits 11,621 15,242 Income tax receivable 10,703 72,371 Total current assets 11,830,556 12,126,396 Property, plant and equipment – net 979,617 993,781 Prepaid land lease payments 65,540 69,815 Intangible assets - net 8,520 9,699 Long-term prepaid expenses 24 23 Long-term investments 684,285 661,440 Prepayments for acquisition of equipment 6,772 120,912 Deferred tax assets 29,790 71,118 Right-of-use assets 45,525 58,586 Other Non-current Assets 7,345 2,798 Total assets 13,657,974 14,114,568 Current liabilities Short-term bank loans and current portion of long-term bank loans 76,089 293 Loan from a non-controlling shareholder - 4,358 Accounts payable and accrued liabilities 973,949 905,923 Income tax payable 41,258 - Deferred revenue 20,127 17,955 Deferred government grants 1,586 15,120 Dividend payable 29,089 141,993 Lease liability 5,806 5,993 Total current liabilities 1,147,904 1,091,635 Deferred revenue 200 - Deferred government grants 5,865 4,477 Long-term bank loans 177,817 11,513 Deferred tax liability 263,711 241,526 Lease liability 39,271 52,516 Other non-current liabilities 439 240 Total long-term liabilities 487,303 310,272 Total liabilities 1,635,207 1,401,907 Commitments and contingencies Equity Preferred stock 15 15 Common stock 100 100 Additional paid-in capital 541,258 540,582 Accumulated other comprehensive income (loss) (490,055) (383,276) Statutory surplus reserves 1,539,584 1,538,013 Accumulated earnings 7,118,516 7,225,987 Total shareholders' equity 8,709,418 8,921,421 Non-controlling interests 3,313,349 3,791,240 Total equity 12,022,767 12,712,661 Total liabilities and equity $ 13,657,974 $ 14,114,568 SINOVAC BIOTECH LTD. Consolidated Statements of Comprehensive Income (Loss) For the six and twelve months ended 2023 and 2022 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended December 31, Year ended December 31, 2023 2022 2023 2022 (Unaudited) (Unaudited) Sales $ 307,865 $ 280,471 $ 448,269 $ 1,492,761 Cost of sales (6,893) 430,094 181,516 684,456 Gross profit 314,758 (149,623) 266,753 808,305 Selling, general and administrative expenses 235,276 667,663 466,324 823,543 Provision for doubtful accounts 2,252 3,461 2,638 4,268 Research and development expenses 193,383 257,714 344,515 442,108 Loss on disposal and impairment of property, plant and equipment 78,408 1,927 78,720 5,213 Government grants recognized in income (22,331) (746) (22,423) (760) Total operating expenses 486,988 930,019 869,774 1,274,372 Operating loss (172,230) (1,079,642) (603,021) (466,067) Interest and financing expenses (1,996) (641) (2,260) (1,264) Interest income 55,525 106,820 85,114 190,818 Other income (expense), net 29,277 72,293 367,133 301,751 Income (loss) before income taxes (89,424) (901,170) (153,034) 25,238 Income tax benefit (expense) (138,918) 198,855 (105,321) 62,893 Net income (loss) (228,342) (702,315) (258,355) 88,131 Less: loss attributable to non-controlling interests 111,506 331,669 158,437 25,735 Net income (loss) attributable to shareholders of Sinovac (116,836) (370,646) (99,918) 113,866 Preferred stock dividends (3,024) (3,024) (5,982) (5,982) Net income (loss) attributable to common shareholders of Sinovac (119,860) (373,670) (105,900) 107,884 Net income (loss) (228,342) (702,315) (258,355) 88,131 Other comprehensive income (loss), net of tax of nil Foreign currency translation adjustments 154,217 (279,794) (280,426) (859,045) Unrealized gain 72,817 - 65,900 - Comprehensive loss (1,308) (982,109) (472,881) (770,914) Less: comprehensive loss attributable to non-controlling interests 48,879 445,656 266,184 370,882 Comprehensive income (loss) attributable to shareholders of Sinovac 47,571 (536,453) (206,697) (400,032) Earnings/loss per share Basic net income (loss) per share (1.20) (3.76) (1.06) 1.08 Diluted net income (loss) per share (1.20) (3.76) (1.06) 1.00 Weighted average number of shares of common stock outstanding Basic 99,638,043 99,502,243 99,607,574 99,502,243 Diluted 99,638,043 99,502,243 99,607,574 114,172,782 SINOVAC BIOTECH LTD. Consolidated Statements of Cash Flows For the six and twelve months ended 2023 and 2022 (Expressed in thousands of U.S. Dollars) Six months ended December 31, Year ended December 31, 2023 2022 2023 2022 (Unaudited) (Unaudited) Operating activities Net income (loss) $ (228,342) $ (702,315) $ (258,355) $ 88,131 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Deferred income taxes 108,448 (67,172) 76,324 (83,010) Share-based compensation - - - - Inventory provision 39,903 83,800 52,527 140,004 Provision for doubtful accounts 2,252 3,461 2,638 4,268 Loss on disposal and impairment of property, plant and equipment 78,408 1,927 78,720 5,213 Depreciation of property, plant and equipment 57,983 78,660 140,467 153,819 Amortization of prepaid land lease payments 1,090 1,374 2,228 1,749 Amortization of intangible assets 1,523 932 2,050 1,029 Government grants recognized in income (5,518) (746) (22,423) (760) Investment income (172,847) - (248,085) - Changes in: Accounts receivable (8,287) 429,615 82,147 289,600 Inventories 6,530 (6,869) (16,766) 30,382 Income tax (recoverable) payable 107,202 (191,672) 101,378 (1,275,296) Prepaid expenses and deposits 1,682 (111,395) 3,265 22,519 Deferred revenue 4,957 (13,364) 2,883 (58,485) Accounts payable and accrued liabilities 156,638 536,063 109,430 (86,860) Other non-current assets/liabilities (7,634) (5,531) (4,431) (3,048) Net cash provided by (used in) operating activities 143,988 36,768 103,997 (770,745) Financing activities Proceeds from bank loans 33,808 1 243,395 151 Repayments of bank loans (158) (48) (308) (2,981) Proceeds from issuance of common stock, net of share issuance costs - - 676 - Dividend paid (326,464) (260,702) (328,080) (263,171) Proceeds from subsidiary's financing - - - 11,291 Government grants received 3,831 9,776 12,499 14,797 Repayments of loan from a non-controlling shareholder (4,244) (1,474) (4,245) (1,486) Net cash used in financing activities (293,227) (252,447) (76,063) (241,399) Investing activities Purchase of investments (1,593,895) (5,717,991) (8,222,005) (11,658,465) Proceeds from redemption and sales of investments 1,561,769 3,619,956 5,575,287 6,327,521 Proceeds from disposal of equipment 2 5 39 608 Proceeds from dissolution of subsidiary - 114,352 - 114,352 Acquisition of property, plant and equipment (51,601) (114,402) (144,543) (393,800) Prepaid land lease payments - (26,025) - (35,683) Acquisition of intangible assets (1,145) (9,568) (1,145) (9,568) Purchase of equity investments (108,975) (42,155) (133,767) (105,435) Distributions by equity method investees 679 - 2,021 - Net cash used in investing activities (193,166) (2,175,828) (2,924,113) (5,760,470) Effect of exchange rate changes on cash and cash equivalents and restricted cash (29,058) (189,210) (114,901) (560,769) Decrease in cash and cash equivalents and restricted cash (371,463) (2,580,717) (3,011,080) (7,333,383) Cash and cash equivalents and restricted cash, beginning of period 1,646,760 6,867,094 4,286,377 11,619,760 Cash and cash equivalents and restricted cash, end of period 1,275,297 4,286,377 1,275,297 4,286,377 SINOVAC BIOTECH LTD. Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures For the six and twelve months ended 2023 and 2022 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended December 31, Year ended December 31, 2023 2022 2023 2022 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net income (loss) $ (228,342) $ (702,315) $ (258,355) $ 88,131 Adjustments: Depreciation and amortization 60,596 80,966 144,745 156,597 Interest and financing expenses, net of interest income (53,529) (106,179) (82,854) (189,554) Other expense (income), net (29,277) (72,293) (367,133) (301,751) Income tax (benefit) expense 138,918 (198,855) 105,321 (62,893) Non-GAAP adjusted EBITDA (111,634) (998,676) (458,276) (309,470) Net income (loss) (228,342) (702,315) (258,355) 88,131 Add: Foreign exchange (gain) loss 45,308 (103,472) (45,543) (265,091) Non-GAAP net loss (183,034) (805,787) (303,898) (176,960) Net income (loss) attributable to common shareholders of Sinovac (119,860) (373,670) (105,900) 107,884 Add: Non-dilutive preferred stock dividends - - - 5,982 Net income (loss) attributable to common shareholders of Sinovac for computing diluted earnings per share (119,860) (373,670) (105,900) 113,866 Add: Non-GAAP adjustments to net income (loss) 27,280 (61,239) (26,069) (156,332) Non-GAAP net loss attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share (92,580) (434,909) (131,969) (42,466) Weighted average number of shares on a diluted basis 99,638,043 99,502,243 99,607,574 114,172,782 Diluted earnings (loss) per share (1.20) (3.76) (1.06) 1.00 Add: Non-GAAP adjustments to net income (loss) per share 0.27 (0.62) (0.26) (1.37) Non-GAAP diluted earnings (loss) per share (0.93) (4.38) (1.32) (0.37)